Akari Therapeuticsplc Is A Clinical Stage Biopharmaceutical Company Focused On Developing Innovative Treatments For Cancer Through Next Generation Precision Bi Functional Antibody Drug Conjugatesadcs The Company Has Shifted Its Primary Focus To Oncologyutilizing Its Adc Technology To Target Various Types Of Cancerits Lead Candidateaktx 101Targets The Trop2 Receptor On Cancer Cells And Employs A Proprietary Linker To Deliver A Novel Ph1 Payloadwhich Disrupts Rna Splicing And Induces Tumor Specific Cell Death Headquartered In Both Boston And Londonakari Therapeutics Has Made Significant Leadership Changes To Enhance Its Expertise In Oncologywith Abizer Gaslightwala Appointed As President And Ceothe Company S Adc Discovery Platform Supports The Development Of Novel Bi Functional Adc Candidatesaddressing Multiple Indications Across Solid And Hematological Cancersakari Is Well Positioned To Advance Its Pipeline And Explore Opportunities For Non Dilutive Capital Through Partnerships
